Cytokinetics raises $805M from public stock offering including full exercise of underwriters' option.

Cytokinetics completed a public offering of 11.3 million common shares at $71 each, raising approximately $805 million before expenses. The offering included the full exercise of underwriters' option to purchase an additional 1.48 million shares. Proceeds will support the company's development of cardiovascular biopharmaceuticals, including treatments for heart muscle diseases. This capital boost strengthens Cytokinetics' pipeline and ongoing research efforts in cardiac muscle dysfunction therapies.